3X (DYKDDDDK) Peptide | CAS# 402750-12-3 APExBIO 貨號A6001
特點
生化分析試劑系列商品->>3X (DYKDDDDK) Peptide
APExBIO Technology LLC 是一家領先的小分子抑制劑 (Small Molecule Inhibitors)/活化劑(Activators)、化合物庫( Compound Libraries)、胜肽(Peptides)、檢測試劑盒(Assay Kits)、螢光標記(Fluorescent Label)、酶(Enzymes)、修飾核苷酸(Modified Nucleotides)、mRNA 合成以及各種分子生物學工具的供應商。APExBIO提供廣泛的產品線，涵蓋 20 多個不同的研究領域，例如癌症(cancer)、免疫學(immunology)、神經科學(neurosciences)、細胞凋亡(apoptosis)和表觀遺傳學(epigenetics)等。公司總部位於美國德州休士頓USA (Houston, Texas)，致力於服務全球客戶。高度重視產品品質。所有產品均遵循嚴格的生產指南，並附有分析證書、HPLC、質譜(Mass Spectrum)和HMNR以及體外驗證(in vitro validation)。 APExBIO產品已被《Nature》、《Cell》和《Science》等眾多頂級同行評審期刊引用。
3X (DYKDDDDK) Peptide | CAS# 402750-12-3 APExBIO 貨號A6001
DYKDDDDK-tag 系統使用一個短的、具親水8 氨基酸肽(8- amino-acid peptide)，與目標蛋白質融合。 DYKDDDDK 肽與抗體 M1 結合。該系統的一個缺點是單克隆抗體純化基質不如其他純化基質穩定。一般來說，小標籤可以用特異性單克隆抗體檢測。為了改進對 DYKDDDDK 標籤的檢測，開發了 3x (DYKDDDDK) 系統。這個三串聯 DYKDDDDK 表位是親水的，22 個氨基酸長，可以檢測高達 10 fmol 的表達融合蛋白。 Pyrococcus furiosus 的 DYKDDDDK 標記的麥芽糖糊精結合蛋白結晶 ，晶體的質量與未標記蛋白質的晶體非常相似。最後，可以通過腸激酶處理去除 DYKDDDDK 標籤，腸激酶對肽序列的五個 C 末端氨基酸具有特異性。
- 1. Wei Yuan, Qais Al-Hadid, et al. “TDRD3 promotes DHX9 chromatin recruitment and R-loop resolution.” Nucleic Acids Res. 2021 Sep 7;49(15):8573-8591. PMID:34329467
- 2. Daniel L. Kober, Arun Radhakrishnan, et al. “Scap structures highlight key role for rotation of intertwined luminal loops in cholesterol sensing.” Cell. 2021 Jul 8;184(14):3689-3701.e22. PMID:34139175
- 3. Haijing Guo, Jen-Hsuan Wei, et al. “Importin α phosphorylation promotes TPX2 activation by GM130 to control astral microtubules and spindle orientation.” J Cell Sci. 2021 Feb 19;134(4):jcs258356. PMID:33526712
- 4. Wu Y, Jin S, et al. “Selective autophagy controls the stability of transcription factor IRF3 to balance type I interferon production and immune suppression.” Autophagy. 2020;1-14. PMID:32476569
- 5. Howard SM, Ceppi I, et al. “The internal region of CtIP negatively regulates DNA end resection.” Nucleic Acids Res. 2020;48(10):5485-5498. PMID:32347940
- 6. Jesse R. Poganik, Alexandra K. Van Hall-Beauvais, et al. “The mRNA-binding protein HuR is a kinetically-privileged electrophile sensor.” Helvetica Chimica Acta.10.1002.
| Storage | Desiccate at -20°C |
| M.Wt | 2861.87 |
| Cas No. | 402750-12-3 |
| Formula | C120H169N31O49S |
| Synonyms | H-Met-Asp-Tyr-Lys-Asp-His-Asp-Gly-Asp-Tyr-Lys-Asp-His-Asp-Ile-Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys-OH |
| Solubility | ≥25mg/ml in TBS (0.5M Tris-HCl, pH 7.4, with 1M NaCl), 1X TBS as recommended buffer. |
| Chemical Name | 3X (DYKDDDDK) Peptide |
| SDF | Download SDF |
| Shipping Condition | Ship with blue ice, or upon other requests. |
| General tips | For obtaining a higher solubility, please warm the tube at 37°C and shake it in the ultrasonic bath for a while. We do not recommend long-term storage for the solution, please use it up soon. |
APExBIO台灣代理商: https://www.apexbt.com/
APExBIO提供優質的胜肽和生物分析試劑，廣泛產品線如Protease、Chromatin/Epigenetics表觀遺傳學、MAPK Signal、DNA Damege/DNA repair、細胞凋亡、腫瘤生物學、Stem cell等研究領域， 還提供定制的服務，包括多肽合成，抗體的生產和檢測的發展。產品線DNA/RNA prep kit、Drug Screening panel、Bioactive peptides、Growth factors、Biotinylation Reagents、tag peptides、amino Acids、Growth factors等。APExBIO產品質量都伴隨著證書的分析，高效液相色譜，質譜，和HMNR數據。
| A2601 | Aclacinomycin A | 57576-44-0 | 98.00% | Topoisomerase I and II inhibitor |
| A2602 | Calpain Inhibitor I, ALLN | 110044-82-1 | 98.00% | Calpain I/II/ B/L inhibitor |
| A2603 | Calpain Inhibitor II, ALLM | 136632-32-1 | 98.00% | Calpain inhibitor |
| A2604 | Celastrol | 34157-83-0 | 98.67% | Antioxidant, anti-inflammatory and immunosuppressive agent |
| A2606 | Epoxomicin | 134381-21-8 | 97.92% | Proteasome inhibitor |
| A2610 | Fenbendazole | 43210-67-9 | 99.57% | For pinworm treatment in animals |
| A2612 | MG-115 | 133407-86-0 | 98.00% | Potent reversible proteasome inhibitor |
| A2614 | Bortezomib (PS-341) | 179324-69-7 | 99.89% | Proteasome Inhibitor |
| A2623 | VU 0364439 | 1246086-78-1 | 98.00% | Positive allosteric mGluR-4 modulator |
| A2633 | Brivanib Alaninate (BMS-582664) | 649735-63-7 | 98.00% | VEGFR2 inhibitor,ATP-competitive |
| A2664 | VX-661 | 1152311-62-0 | 99.88% | F508del CFTR corrector |
| A2673 | AG-1024 | 65678-07-1 | 98.00% | Selective IGF-1R inhibitor |
| A2678 | SU11274 | 658084-23-2 | ≥95.00% | C-Met inhibitor,potent and selective |
| A2681 | TGX-221 | 663619-89-4 | 98.91% | PI3Kβ inhibitor,potent,selective and ATP competitive |
| A2689 | Butein | 487-52-5 | 98.00% | Protein kinase inhibitor |
| A2700 | 10Panx | 955091-53-9 | 99.29% | Panx-1 mimetic inhibitor |
| A2701 | Scrambled 10Panx | 1315378-72-3 | 98.68% | Panx-1 mimetic inhibitory peptide, blocks pannexin-1 gap junctions |
| A2754 | TG100-115 | 677297-51-7 | 98.02% | PI3Kγ/PI3Kδ inhibitor |
| A2782 | Amonafide | 69408-81-7 | 98.00% | DNA intercalator,Topo II inhibitor |
| A2806 | BX-912 | 702674-56-4 | 95.55% | PDK1 inhibitor,potent and ATP-competitive |
| A2813 | Ivermectin | 70288-86-7 | 98.00% | NAChR/purinergic P2X4 receptor modulator |
| A2822 | AC480 (BMS-599626) | 714971-09-2 | 98.00% | HER1/2 inhibitor,selective and efficacious |
| A2838 | OSI-930 | 728033-96-3 | 99.58% | Inhibitor of Kit, KDR, Flt, CSF-1R, c-Raf and Lck |
| A2842 | Melatonin | 73-31-4 | 99.81% | Melatonin receptors agonist |
| A2845 | Omeprazole | 73590-58-6 | 97.37% | H+,K+-ATPase inhibitor |
| A2846 | OSU-03012 (AR-12) | 742112-33-0 | 99.43% | Potent PDK1 inhibitor |
| A2852 | Leflunomide | 75706-12-6 | 99.69% | AHR agonist,immunosuppressive agent |
| A2884 | Doxazosin Mesylate | 77883-43-3 | 99.82% | α1-adrenergic receptor antagonist |
| A2890 | Nepafenac | 78281-72-8 | 98.00% | COX-1 and COX-2 inhibitor |
| A2917 | Flumazenil | 78755-81-4 | 99.85% | Benzodiazepine antagonist |
| A2942 | Masitinib (AB1010) | 790299-79-5 | 99.60% | Tyrosine kinase inhibitor, potent and selective |
| A2949 | Linifanib (ABT-869) | 796967-16-3 | 99.62% | VEGFR/PDGFR inhibitor |
| A2960 | Loratadine | 79794-75-5 | 98.24% | Peripheral HH1R antagonist |
| A2974 | Foretinib (GSK1363089) | 849217-64-7 | 98.36% | VEGF and HGF receptor inhibitor |
| A2977 | Cabozantinib (XL184, BMS-907351) | 849217-68-1 | 98.60% | VEGFR2/Met/Ret/Kit/FLT//AXL inhibitor |
| A2986 | ADL5859 HCl | 850173-95-4 | 99.16% | δ-opioid receptor agonist,selective |
| A3001 | PCI-32765 (Ibrutinib) | 936563-96-1 | 99.39% | Bruton’s tyrosine kinase (BTK) inhibitor |
| A3002 | ABT-888 (Veliparib) | 912444-00-9 | 99.87% | Potent PARP inhibitor |
| A3003 | MDV3100 (Enzalutamide) | 915087-33-1 | 99.78% | Androgen receptor antagonist |
| A3004 | Vemurafenib (PLX4032, RG7204) | 918504-65-1 | 98.48% | BRAF kinase inhibitor |
| A3005 | CAL-101 (Idelalisib, GS-1101) | 870281-82-6 | 99.91% | PI3K inhibitor |
| A3006 | GDC-0068 (RG7440) | 1001264-89-6 | 99.06% | Pan-AKT inhibitor,highly selective |
| A3007 | ABT-263 (Navitoclax) | 923564-51-6 | 98.02% | Potent Bcl-2 family inhibitor, inhibits Bcl-2, Bcl-xL, and Bcl-w |
| A3008 | Y-27632 dihydrochloride | 146986-50-7;129830-38-2 | 99.08% | ROCK1 inhibitor |
| A3009 | Sorafenib | 284461-73-0 | 99.87% | Raf kinases and tyrosine kinases inhibitor |
| A3010 | MK-2206 dihydrochloride | 1032350-13-2 | 99.59% | Akt1/2/3 inhibitor |
| A3011 | CHIR-99021 (CT99021) | 252917-06-9 | 98.32% | GSK-3 inhibitor, Cell-permeable, ATP-competitive |
| A3012 | Ruxolitinib (INCB018424) | 941678-49-5 | 99.64% | JAK inhibitor |
| A3013 | PD0325901 | 391210-10-9 | 99.74% | MEK inhibitor |
| A3014 | BGJ398 | 872511-34-7 | 99.74% | FGFR inhibitor ,potent and selective |
| A3015 | BKM120 | 944396-07-0 | 98.01% | Inhibitor of pan-Class I PI3K |
| A3016 | PLX-4720 | 918505-84-7 | 98.70% | BRAF kinase inhibitor |
| A3017 | Dasatinib (BMS-354825) | 302962-49-8 | 98.09% | Src and BCR-Abl inhibitor |
| A3018 | Trametinib (GSK1120212) | 871700-17-3 | 98.98% | MEK1 and MEK2 inhibitor, potent and selective |
| A3019 | AT-406 (SM-406) | 1071992-99-8 | 98.00% | IAP inhibitor |
| A3021 | GDC-0449 (Vismodegib) | 879085-55-9 | 99.64% | Hedgehog antagonist,potent and selective |
| A3022 | Pazopanib (GW-786034) | 444731-52-6 | 98.81% | VEGFR/PDGFR/FGFR inhibitor |
| A3023 | P005091 | 882257-11-6 | 99.67% | Ubiquitin-specific protease 7 (USP7) inhibitor |
| A3100 | (+)-MK 801 | 70449-94-4 | 99.38% | Potent NMDA antagonist |
| A3104 | (E)-2-Decenoic acid | 334-49-6 | 98.00% | Fatty acid identified in royal jelly |
| A3108 | 17 alpha-propionate | 19608-29-8 | 98.00% | Androgen antagonist |
| A3111 | 1alpha, 25-Dihydroxy VD2-D6 | 216244-04-1 | 98.00% | Deuterated form of vitamin D |
| A3115 | 24, 25-Dihydroxy VD3 | 40013-87-4 | 98.00% | Vitamin D analogue |
| A3118 | 3,3′-Diindolylmethane | 1968-05-4 | 99.69% | Anticancer and antineoplastic agent |
| A3119 | 360A | 794458-56-3 | 98.00% | G-quadruplex structures inhibitor |
| A3120 | 360A iodide | 737763-37-0 | 98.56% | G-quadruplex structures inhibitor |
| A3122 | PI4KIII beta inhibitor 3 | 1245319-54-3 | 98.00% | PI4KIII beta inhibitor |
| A3123 | 4′-Demethylepipodophyllotoxin | 6559-91-7 | 99.32% | Anti-cancer drug |
| A3124 | 5-hydroxypyrazine-2-carboxylic acid | 34604-60-9 | 99.15% | Metabolite of pyrazinamide (PZA) |
| A3125 | 5-Iodotubercidin | 24386-93-4 | 98.34% | Adenosine kinase inhibitor,potent |
| A3126 | 5-R-Rivaroxaban | 865479-71-6 | 99.49% | Factor Xa (FXa) inhibitor |
| A3130 | A 438079 | 899507-36-9 | 98.00% | P2X7 receptor antagonist,competitive and selective |
| A3131 | A 438079 hydrochloride | 899431-18-6 | 99.59% | P2X7 receptor antagonist,competitive and selective |
| A3132 | A 77-01 | 607737-87-1 | 99.50% | Potent ALK5 inhibitor |
| A3133 | A 83-01 | 909910-43-6 | 99.24% | ALK-5 inhibitor |
| A3134 | A-317491 | 475205-49-3 | 98.53% | P2X3 and P2X2/3 receptor antagonist |
| A3135 | A-443654 | 552325-16-3 | 99.79% | Akt inhibitor,potent and selective |
| A3136 | A-740003 | 861393-28-4 | 98.24% | P2X7 receptor antagonist |
| A3138 | A-867744 | 1000279-69-5 | 98.00% | Allosteric Modulator |
| A3139 | Abacavir | 136470-78-5 | 99.89% | Inhibitor of HIV reverse transcriptase |
| A3142 | Acamprosate calcium | 77337-73-6 | 99.78% | GABA receptor agonist and modulator of glutamatergic systems |
| A3143 | Adarotene | 496868-77-0 | 99.24% | Apoptosis inducer/DNA damage agent |
| A3145 | Afatinib dimaleate | 850140-73-7 | 99.49% | EGFR inhibitor |
| A3146 | AGI-6780 | 1432660-47-3 | 98.63% | IDH2/R140Q mutation inhibitor |
| A3147 | AH 6809 | 33458-93-4 | 98.00% | EP and DP receptor antagonist |
| A3148 | AIM-100 | 873305-35-2 | 98.95% | Ack1 inhibitor |
| A3149 | AKT inhibitor VIII | 612847-09-3 | 99.73% | Allosteric Akt kinase inhibitor |
| A3151 | Alarelin Acetate | 79561-22-1 | 99.88% | Synthetic GnRH agonist |
| A3153 | Aliskiren | 173334-57-1 | 98.95% | Direct renin inhibitor |
| A3155 | ALK inhibitor 2 | 761438-38-4 | 98.00% | ALK inhibitor, novel and selective |
| A3156 | Alogliptin Benzoate | 850649-62-6 | 98.00% | DPP-4 inhibitor,selective and potent,antidiabetic drug |
| A3157 | Alosetron | 122852-42-0 | 98.00% | 5-HT3 receptor antagonist |
| A3159 | Alosetron Hydrochloride | 122852-69-1 | 98.91% | 5-HT3 receptor antagonist,potent and highly selective |
| A3162 | Alvimopan | 156053-89-3 | 99.67% | Mu-opioid receptors antagonist |
| A3163 | Alvimopan dihydrate | 170098-38-1 | 98.00% | μ-opioid receptor antagonist,peripherally acting |
| A3165 | ALW-II-41-27 | 1186206-79-0 | 97.45% | Eph receptor inhibitor |
| A3166 | AM095 | 1345614-59-6 | 98.14% | Potent LPA1 receptor antagonist |
| A3167 | AM-095 free base | 1228690-36-5 | 98.12% | Potent LPA1 receptor antagonist |
| A3169 | AM679 | 1206880-66-1 | 98.00% | FLAP inhibitor |
| A3170 | AM966 | 1228690-19-4 | 99.69% | LPA1 antagonist, oral active, high affinity, selective, |
| A3171 | Amadacycline | 389139-89-3 | 99.46% | Tetracycline antibiotic |
| A3173 | AMD-070 | 558447-26-0 | 98.00% | CXCR4 antagonist,potent and selective |
| A3174 | AMD-070 hydrochloride | 880549-30-4 | 98.00% | CXCR4 antagonist,potent and selective |
| A3176 | Ampalex | 154235-83-3 | 98.54% | Ampakine and nootropic |
| A3177 | AN-2690 | 174671-46-6 | 98.60% | Antifungal agent |
| A3178 | AN-2728 | 906673-24-3 | 99.33% | PDE4 inhibitor,anti-inflammatory compound |
| A3179 | Anamorelin | 249921-19-5 | 99.68% | Ghrelin receptor agonist, synthetic, orally active |
| A3182 | Anguizole | 442666-98-0 | 98.00% | Inhibitor of HCV replication |
| A3184 | AR-A014418 | 487021-52-3 | 98.34% | GSK3β inhibitor, ATP-competitive and selective |
| A3185 | AR-C155858 | 496791-37-8 | 99.52% | MCT1 and MCT2 inhibitor |
| A3188 | ARRY-520 R enantiomer | 885060-08-2 | 98.00% | KSP inhibitor |
| A3189 | AS 602801 | 848344-36-5 | 98.72% | Jun Kinase Inhibitor |
| A3190 | ASC-J9 | 52328-98-0 | 98.00% | AR degradation enhancer,antiumor agent |
| A3191 | Ascomycin(FK 520) | 104987-12-4 | 98.00% | Macrolide immunosuppressant,FK-520 analog |
| A3192 | Asenapine hydrochloride | 1412458-61-7 | 98.00% | Atypical antipsychotic |
| A3193 | ASP3026 | 1097917-15-1 | 99.38% | ALK inhibitor,potent and selective |
| A3194 | AST 487 | 630124-46-8 | 99.29% | RET kinase inhibitor |
| A3195 | Asunaprevir (BMS-650032) | 630420-16-5 | 99.80% | NS3 protease inhibitor |
| A3196 | AT-101 | 90141-22-3 | 98.00% | BH3-mimetic,gossypol enantiomer |
| A3197 | AT7519 Hydrochloride | 902135-91-5 | 99.80% | Multi-CDK inhibitor |
| A3198 | AT7519 trifluoroacetate | 1431697-85-6 | 98.00% | CDK/cyclin inhibitor |
| A3199 | AT7867 dihydrochloride | 1431697-86-7 | 98.00% | Akt1 and p70S6K/PKA inhibitor |
| A3201 | Atrasentan hydrochloride | 195733-43-8 | 98.00% | Endothelin receptor antagonist |
| A3202 | Avermectin B1 | 71751-41-2 | 98.00% | Insecticide |
| A3206 | AVL-292 | 1202757-89-8 | 98.27% | Btk inhibitor |
| A3208 | Avosentan | 290815-26-8 | 98.00% | ETA receptor antagonist |
| A3209 | AXL1717 | 477-47-4 | 98.07% | IGF-1R inhibitor,orally active |
| A3210 | AZ20 | 1233339-22-4 | 99.93% | ATR inhibitor,potent and selective |
| A3214 | AZD1152 | 722543-31-9 | 98.78% | Aurora B kinase inhibitor,highly potent and selective |
| A3215 | AZD7687 | 1166827-44-6 | 98.00% | DGAT inhibitor,potent and selective |
| A3216 | Balaglitazone | 199113-98-9 | 99.62% | PPAR-γ partial agonist |
| A3217 | Balapiravir | 690270-29-2 | 98.00% | Polymerase inhibitor,anti-HCV |
| A3218 | BAM7 | 331244-89-4 | 98.00% | BAX activator,direct and selective |
| A3219 | BAN ORL 24 | 475150-69-7 | 98.00% | NOP receptor antagonist, potent and selective |
| A3220 | Bardoxolone | 218600-44-3 | 99.55% | Once-a-day treatment for CKD |
| A3221 | Bardoxolone methyl | 218600-53-4 | 98.75% | IKK inhibitor, potent antioxidant inflammation modulator |
| A3222 | Baricitinib phosphate | 1187595-84-1 | 99.59% | JAK1/JAK2 inhibitor |
| A3227 | BAY 61-3606 | 732983-37-8 | 98.45% | Syk Inhibitor |
| A3228 | BAY 61-3606 dihydrochloride | 648903-57-5 | 98.00% | Syk tyrosine kinase inhibitor |
| A3230 | Bay 65-1942 HCl salt | 600734-06-3 | 98.00% | IKKβ kinase inhibitor |
| A3232 | Bazedoxifene | 198481-32-2 | 98.00% | Estrogen receptor modulator |
| A3236 | Benfotiamine | 22457-89-2 | 99.76% | Drug for painful nerve condition |
| A3237 | Betulinic acid | 472-15-1 | 98.00% | Anti-HIV and antitumor compound,pentacyclic triterpenoid |
| A3238 | BEZ235 Tosylate | 1028385-32-1 | 98.28% | MTOR/P13K inhibitor |
| A3239 | B-HT 920 | 36085-73-1 | 98.00% | D2 receptor agonist |
| A3240 | BIBX 1382 | 196612-93-8 | 98.00% | EGFR inhibitor,potent and selective |
| A3241 | Bilobalide | 33570-04-6 | 98.00% | Neuroprotective agent |
| A3242 | Bitopertin | 845614-11-1 | 99.70% | Glycine reuptake inhibitor(GlyT1) |
| A3244 | Bivalirudin Trifluoroacetate | 128270-60-0 | 98.07% | Reversible thrombin inhibitor |
| A3246 | BMN-673 8R,9S | 1207456-00-5 | 99.75% | Inactive form of BMN 673, used as negative control |
| A3248 | BMS345541 hydrochloride | 547757-23-3 | 99.57% | IKK inhibitor,highly selective |
| A3250 | BMS-509744 | 439575-02-7 | 98.00% | Itk inhibitor,potent and selective |
| A3252 | BMS-599626 Hydrochloride | 873837-23-1 | 99.58% | EGFR/HER2 inhibitor,potent and selective |
| A3253 | BMS-626529 | 701213-36-7 | 98.01% | HIV-1 attachment inhibitor |
| A3254 | BMS-663068 | 864953-29-7 | 98.00% | HIV-1 attachment inhibitor |
| A3256 | BMS-690514 | 859853-30-8 | 98.00% | HER/EGFR inhibitor |
| A3257 | BMS-790052 dihydrochloride | 1009119-65-6 | 99.81% | HCV NS5A inhibitor |
| A3258 | BMS-833923 | 1059734-66-5 | 99.84% | Smoothened inhibitor |
| A3259 | BMS-927711 | 1289023-67-1 | 98.99% | CGRP receptor antagonist |
| A3260 | BMX-IN-1 | 1431525-23-3 | 97.99% | BMX (also termed ETK) kinase inhibitor |
| A3261 | Boceprevir | 394730-60-0 | 98.00% | HCV protease inhibitor,potent and selective |
| A3263 | BRAF inhibitor | 918505-61-0 | 98.00% | Potent B-raf inhibitor |
| A3264 | B-Raf inhibitor | 1315330-11-0 | 98.00% | A B-Raf inhibitor |
| A3265 | Brassinolide | 72962-43-7 | 98.00% | Plant growth regulator |
| A3266 | BS-181 | 1092443-52-1 | 98.00% | CDK7 inhibitor,highly selective |
| A3268 | CAL-130 Hydrochloride | 1431697-78-7 | 98.00% | PI3K inhibitor |
| A3270 | Calcifediol monohydrate | 63283-36-3 | 99.43% | Prehormone;vitamin D3 metabolite |
| A3271 | Calcipotriol | 112965-21-6 | 98.00% | Vitamin D3 analog,regulates cell differentiation and proliferation |
| A3275 | Calcium-Sensing Receptor Antagonists I | 478963-79-0 | 98.00% | CaSR antagonist |
| A3276 | Canertinib dihydrochloride | 289499-45-2 | 99.72% | Pan-ErbB inhibitor, potent and selective |
| A3277 | Capadenoson | 544417-40-5 | 98.00% | Adenosine A1 receptor agonist |
| A3278 | Nonivamide (Capsaicin Analog) | 2444-46-4 | 99.53% | TRPV1 receptor agonist |
| A3279 | Capsazepine | 138977-28-3 | 99.25% | TRPV1 ion channel antagonist |
| A3282 | Cariprazine | 839712-12-8 | 99.19% | D2/D3 partial agonist,antipsychotic drug |
| A3284 | Cathepsin S inhibitor | 1373215-15-6 | 98.33% | Blocks MHCII antigen presentation |
| A3285 | CB 300919 | 289715-28-2 | 98.00% | Potential therapy for ovarian cancer |
| A3286 | CB30865 | 206275-15-2 | 98.00% | Nampt inhibitor |
| A3287 | CC-401 hydrochloride | 1438391-30-0 | 98.00% | JNK inhibitor |
| A3288 | CC-930 | 899805-25-5 | 98.00% | JNK inhibitor,potent and selective |
| A3289 | CCG-63802 | 620112-78-9 | 98.00% | RGS protein inhibitor |
| A3290 | CCG-63808 | 620113-73-7 | 98.00% | Reversible RGS inhibitor |
| A3291 | CCT241533 | 1262849-73-9 | 98.00% | Potent Chk2 inhibitor |
| A3292 | CCT241533 hydrochloride | 1431697-96-9 | 98.00% | CHK2 kinase inhibitor, novel |
| A3293 | CDK inhibitor II | 1269815-17-9 | 98.00% | CDK inhibitor |
| A3294 | CDK9 inhibitor | 1415559-43-1 | 98.00% | CDK9 inhibitor |
| A3295 | CDK9 inhibitor 2 | 1263369-28-3 | 98.00% | CDK9 inhibitor |
| A3297 | CEP-32496 hydrochloride | 1227678-26-3 | 98.00% | B-Raf/C-Raf inhibitor,highly potent |
| A3298 | Cetirizine | 83881-51-0 | 99.65% | Antihistamine |
| A3300 | Cevimeline hydrochloride hemihydrate | 153504-70-2 | 98.00% | Agonist of muscarinic receptor (M1/M3) |
| A3302 | CGI-1746 | 910232-84-7 | 98.00% | Btk inhibitor |
| A3303 | CGP60474 | 164658-13-3 | 98.00% | CDKs and PKC inhibitor, potent |
| A3304 | CGS 21680 | 120225-54-9 | 98.00% | Adenosine A2 receptor agonists,potent and selective |
| A3305 | CHAPS | 75621-03-3 | 97.71% | Zwitterionic detergent for membrane proteins,nondenaturing |
| A3306 | Chelerythrine Chloride | 3895-92-9 | 99.36% | PKC antagonist |
| A3307 | CHIR-090 | 728865-23-4 | 99.37% | Potent LpxC inhibitor |
| A3308 | Choline Fenofibrate | 856676-23-8 | 99.92% | Choline salt of fenofibric acid |
| A3309 | CHR-6494 | 1333377-65-3 | 98.00% | Haspin inhibitor,potent ands selective |
| A3310 | chroman 1 | 1273579-40-0 | 98.00% | ROCK II inhibitor, highly potent and selective |
| A3311 | CID-2858522 | 758679-97-9 | 98.00% | NF-κB pathway inhibitor |